Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
18.8M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
13.9M
-
Shares change
-
+13.9M
-
Total reported value, excl. options
-
$111M
-
Value change
-
+$111M
-
Number of buys
-
30
-
Price
-
$8.03
Significant Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) as of Q1 2025
31 filings reported holding KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.9M shares
of 18.8M outstanding shares and own 73.65% of the company stock.
Largest 10 shareholders include SAMSARA BIOCAPITAL, LLC (11.4M shares), GILEAD SCIENCES, INC. (723K shares), Octagon Capital Advisors LP (481K shares), TANG CAPITAL MANAGEMENT LLC (309K shares), Siren, L.L.C. (283K shares), EcoR1 Capital, LLC (202K shares), VANGUARD GROUP INC (115K shares), Redmile Group, LLC (83K shares), BlackRock, Inc. (27.5K shares), and GEODE CAPITAL MANAGEMENT, LLC (26.8K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.